Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings (2014)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- Subjects: LINFOMA (CLASSIFICAÇÃO); SOBREVIDA; TESTES SOROLÓGICOS; IMUNOHISTOQUÍMICA
- Language: Inglês
- Imprenta:
- Source:
- Título: Blood
- Volume/Número/Paginação/Ano: v. 124, n. 21, suppl, 2014
- Conference titles: Annual Meeting and Exposition / ASH
-
ABNT
MACIEL, Felipe V. Rodrigues et al. Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/124/21/5437?sso-checked=true. Acesso em: 27 dez. 2025. , 2014 -
APA
Maciel, F. V. R., Szor, R. S., Levy, D., Santucci, R., & Pereira, J. (2014). Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/124/21/5437?sso-checked=true -
NLM
Maciel FVR, Szor RS, Levy D, Santucci R, Pereira J. Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings [Internet]. Blood. 2014 ; 124( 21):[citado 2025 dez. 27 ] Available from: http://www.bloodjournal.org/content/124/21/5437?sso-checked=true -
Vancouver
Maciel FVR, Szor RS, Levy D, Santucci R, Pereira J. Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings [Internet]. Blood. 2014 ; 124( 21):[citado 2025 dez. 27 ] Available from: http://www.bloodjournal.org/content/124/21/5437?sso-checked=true - Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort
- Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
